TransCode Therapeutics Financial Overview
TransCode Therapeutics's market cap is currently $7.26M. The company's EPS TTM is $-56.608; its P/E ratio is -0.03; TransCode Therapeutics is scheduled to report earnings on March 28, 2025, and the estimated EPS forecast is $-105.93. See an overview of income statement, balance sheet, and cash flow financials.
